Featuring perspectives from Dr Haley Ellis, Dr Sara Lonardi and Dr Kanwal Raghav, moderated by Dr Christopher Lieu, including the following topics:

• Introduction (0:00)
• Gastroesophageal Cancers — Dr Lonardi (1:54)
• Biliary Tract Cancers — Dr Ellis (39:20)
• Colorectal Cancer — Dr Raghav (1:07:10)

CME information and select publications

Featuring perspectives from Dr Jacqueline Broadway-Duren, Dr Bita Fakhri, Ms Corinne Hoffman and Dr Jeff Sharman, including the following topics:

• Introduction: Key Factors in the Management of Chronic Lymphocytic Leukemia (CLL) (0:00)
• Role of Covalent Bruton Tyrosine Kinase (BTK) Inhibitors for Newly Diagnosed CLL (12:02)
• Role of Time-Limited Up-Front Treatment, Including Therapy Combining BTK Inhibitors and Venetoclax, for Newly Diagnosed CLL (37:55)
• Role of Pirtobrutinib for Relapsed/Refractory (R/R) CLL (1:02:07)
• CAR (Chimeric Antigen Receptor) T-Cell Therapy for R/R CLL (1:16:48)

NCPD information and select publications

Featuring perspectives from Dr Matthew D Galsky, Prof Andrea Necchi and Prof Thomas Powles, moderated by Dr Galsky, including the following topics:

• Introduction (0:00)
• Current and Future Management of Muscle-Invasive Bladder Cancer — Prof Powles (1:14)
• Novel Intravesical Therapies Under Evaluation for Nonmetastatic Urothelial Bladder Cancer (UBC) — Prof Necchi (24:48)
• Selection and Sequencing of Therapy for Metastatic UBC — Dr Galsky (44:52)

CME information and select publications

Featuring perspectives from Dr Jeremy S Abramson, Dr Joshua Brody, Dr Christopher Flowers, Dr Ann LaCasce and Dr Tycel Phillips, moderated by Dr Abramson, including the following topics:

• Introduction (0:00)
• Selection and Sequencing of Available Therapies for Diffuse Large B-Cell Lymphoma — Dr Flowers (2:24)
• Evolving Management Paradigm for Mantle Cell Lymphoma — Dr Phillips (31:53)
• Integration of Novel Therapies into the Management of Follicular Lymphoma — Dr LaCasce (54:51)
• Integrating Bispecific Antibodies into the Management of Non-Hodgkin Lymphoma (NHL) — Dr Brody (1:11:22)
• Current Role of CAR T-Cell Therapy in Various NHL Subtypes — Dr Abramson (1:37:55)

CME information and select publications

Featuring perspectives from Dr Anne Chiang, Ms Elizabeth Krueger, Ms Beth Sandy and Dr Erin Schenk, including the following topics:

• Introduction: Overview of Bispecific Antibodies (0:00)
• Biology of Small-Cell Lung Cancer (SCLC) and Review of Its Initial Management (13:37)
• Case: 63-year-old man — Ms Krueger (23:36)
• Current Role of Tarlatamab in Therapy for SCLC (33:40)
• Case: 70-year-old woman — Ms Sandy (43:41)
• Future Directions in the Management of SCLC (50:45)
• Case: 81-year-old man — Ms Krueger (1:01:24)
• Unique Considerations in SCLC Management (1:09:29)
• Case: 67-year-old woman — Ms Sandy (1:22:53)

NCPD information and select publications

Featuring perspectives from Dr Christopher Flowers, Dr Manali Kamdar, Ms Robin Klebig and Ms Caitlin Murphy, including the following topics:

• Introduction: Overview of Bispecific Antibodies and Chimeric Antigen Receptor T-Cell Therapy for Non-Hodgkin Lymphoma (0:00)
• Current and Future Use of Bruton Tyrosine Kinase Inhibitors for Mantle Cell Lymphoma (16:09)
• First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) (40:03)
• Role of Loncastuximab Tesirine for Patients with Relapsed/Refractory (R/R) DLBCL (57:31)
• Role of Tafasitamab for Patients with R/R DLBCL and Follicular Lymphoma (1:16:59)

NCPD information and select publications

Featuring perspectives from Dr Harold J Burstein, Dr Javier Cortés, Prof Rebecca A Dent, Dr Kevin Kalinsky, Dr Hope S Rugo and Dr Joyce O’Shaughnessy, moderated by Dr Rugo, including the following topics:

• Introduction (0:00)
• Optimizing the Management of HER2-Positive Metastatic Breast Cancer (mBC) — Dr Cortés (3:52)
• Individualized Selection of Up-Front Therapy for Patients with HR-Positive, HER2-Negative mBC — Dr Kalinsky (23:10)
• Available Therapies for Patients with HR-Positive, HER2-Negative Disease Progressing on CDK4/6 Inhibition — Dr Burstein (48:09)
• Current and Potential Future Role of HER2-Targeted Therapy for HER2-Low and HER2-Ultralow Disease — Dr O’Shaughnessy (1:04:00)
• Current and Future Strategies for Patients with Endocrine-Refractory HR-Positive mBC — Dr Rugo (1:22:28)
• Selection and Sequencing of Therapy for Patients with Metastatic Triple-Negative Breast Cancer — Prof Dent (1:42:51)

CME information and select publications

Featuring perspectives from Dr Andrea Cercek, Dr Arvind Dasari, Dr J Randolph Hecht, Dr Pashtoon Kasi and Prof Eric Van Cutsem, moderated by Dr Hecht, including the following topics:

• Introduction (0:00)
• Role of Circulating Tumor DNA (ctDNA) Evaluation in Nonmetastatic Colorectal Cancer (CRC) — Dr Dasari (2:20)
• Role of Immune Checkpoint Inhibitors in the Management of Nonmetastatic Microsatellite Instability-High (MSI-H) CRC — Dr Cercek (28:32)
• Management of Oligometastatic Disease and Hepatic-Only Metastases in CRC; Role of ctDNA Evaluation in Metastatic Disease — Dr Kasi (54:07)
• Role of Immune Checkpoint Inhibitors in the Management of MSI-H Metastatic CRC (mCRC) — Dr Hecht (1:14:34)
• Identification and Care of Patients with mCRC and Actionable Genomic Alterations — Prof Van Cutsem (1:38:17)

CME information and select publications